Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 9 January 2026 - 18 January 2026

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss,…
18 January 2026
····
Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

New York, January 17, 2026, 15:06 (EST) — Market closed Merck & Co (MRK.N) shares dropped 1.9% on Friday, ending the day at $108.83. That’s roughly 4% shy of their 52-week peak of $112.90 hit earlier this month. (Reuters) Investors start the week focused on a new FDA fast-track program targeting quick decisions—just one to two months—on a select group…
17 January 2026
···
Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

ZURICH, Jan 17, 2026, 18:33 CET — Market closed. Novartis AG (NVS) shares ended Friday on a positive note after the Swiss pharma giant revealed that U.S. regulators awarded fast-track designation to its ianalumab programme. This move brings immunology back into focus ahead of the company’s earnings report. (MarketScreener) The FDA’s Breakthrough Therapy designation is designed to accelerate the development…
17 January 2026
···
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

New York, Jan 17, 2026, 06:02 EST — The market has closed. Moderna’s stock climbed 6.3% Friday, closing at $41.83 as the rally that’s been choppy all week gained traction. Since January 12, shares have surged roughly 24%, boosted by a 17% jump on January 13, followed by a short pullback on January 15. (Investing) Investors aren’t focused just on…
17 January 2026
····
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 12:06 (EST) — Regular session Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez…
15 January 2026
···
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

New York, January 13, 2026, 14:47 ET — During regular trading hours Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy. Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan.…
13 January 2026
····
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

NEW YORK, Jan 12, 2026, 10:25 (ET) — Regular session Moderna (MRNA.O) shares dropped roughly 4% on Monday following the release of updated revenue and expense forecasts ahead of a healthcare investor event. The stock fell $1.38 to $32.92, after starting the day at $34.40 and fluctuating between $35.77 and $32.81. This update is crucial as Moderna works to transition…
12 January 2026
····
Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next

Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next

Paris, Jan 12, 2026, 11:17 CET — Regular session Shares in ABIVAX Société Anonyme surged Monday following a French media report that stirred new takeover speculation involving the biotech and U.S. pharmaceutical giant Eli Lilly. (Reuters) The stock climbed roughly 22% to 120.60 euros, hitting a peak of 130 euros earlier, based on Euronext-tracked quotes. It closed at 99 euros…
12 January 2026
···
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

New York, January 10, 2026, 19:54 EST — The market has closed. CG Oncology Inc (CGON) shares surged nearly 29% on Friday, closing at $54.20 after hitting a session high of $57.36. The stock gained $12.25 during the day on volume of about 7.0 million shares. CG Oncology said it now expects “topline” Phase 3 results—the initial look at main…
11 January 2026
····
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

New York, Jan 10, 2026, 14:37 EST — Market closed Merck & Co (MRK) closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion. (Reuters) Timing is crucial. As Merck faces patent losses on its blockbuster cancer drug Keytruda…
10 January 2026
···
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

New York, January 9, 2026, 17:15 ET — After-hours Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares. (Financial…
9 January 2026
···
1 2 3 … 10

Stock Market Today

  • Is It Too Late To Buy Repligen Corporation (NASDAQ:RGEN)?
    January 19, 2026, 6:40 AM EST. Repligen Corporation (NASDAQ:RGEN) has seen a 10% surge in share price recently but remains below its intrinsic value of $233.58, suggesting a potential buying opportunity. The biotech firm's earnings are forecasted to double in the coming years, signaling strong growth prospects. However, its high beta indicates price volatility that may lead to significant swings amid market downturns. Investors should weigh the optimistic outlook against Repligen's financial health and noted warning signs before committing. Current undervaluation may appeal to shareholders and new investors seeking growth, but caution is warranted given market risks and company-specific factors.
Go toTop